Country intelligence
Deals, market moves, science and policy across the platform tagged to Portugal.
Europe's largest cannabis exporter, with tightly restricted domestic patient access.
Market sizing, forecasts, pricing and patient data are available to Prohibition Partners subscribers. View on Prohibition Partners →
Portugal's framework (Law 33/2018 and Decree-Law 8/2019) requires non-pharmaceutical products to obtain a market authorisation (ACM) from INFARMED — a bureaucratic, costly process requiring GACP/GMP evidence — and regulates the commercial supply chain under Ministerial Order 83/2021.
Any doctor may prescribe, but only for specific conditions and as a last resort; in practice few do so owing to limited training. Approved indications include MS/spinal spasticity, treatment-related nausea, palliative appetite stimulation, chronic pain, Tourette's, epilepsy and therapy-resistant glaucoma.
There is no reimbursement; patients pay out of pocket, and prescription numbers remain low relative to other established markets.
Few products are available domestically — a small number of extract products and two flower products — as companies focus on production for export rather than the low-demand home market.
Portugal is the largest European exporter, with exports rising year on year; Germany is by far the biggest destination, followed by Spain, Poland, the UK and Australia. Some companies also package and re-export imports.
A large licensed base spans cultivation, manufacturing and EU-GMP certification, driven by low production costs, an open commercial framework, skilled agricultural labour and a favourable climate.
Nothing tagged to Portugal yet. Tag deals, studies or articles with this country to see them here and on the map.
